147 related articles for article (PubMed ID: 11413853)
1. [Blood lipid abnormalities during treatment with protease inhibitors].
Vergès B; Petit JM
Presse Med; 2001 May; 30(18):911-4. PubMed ID: 11413853
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
Carr A; Samaras K; Chisholm DJ; Cooper DA
Lancet; 1998 Jun; 351(9119):1881-3. PubMed ID: 9652687
[TBL] [Abstract][Full Text] [Related]
3. Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients.
Beatty G; Chu J; Kulkarni K; Lipshutz G; Khalili M; Abbasi F; Stansell J; Reaven GM
HIV Clin Trials; 2004; 5(6):383-91. PubMed ID: 15682351
[TBL] [Abstract][Full Text] [Related]
4. Hyperlipidemia and inhibitors of HIV protease.
Distler O; Cooper DA; Deckelbaum RJ; Sturley SL
Curr Opin Clin Nutr Metab Care; 2001 Mar; 4(2):99-103. PubMed ID: 11224652
[TBL] [Abstract][Full Text] [Related]
5. Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy.
Domingo P; Sambeat MA; Pérez A; Ordoñez J
J Acquir Immune Defic Syndr; 2003 May; 33(1):114-6. PubMed ID: 12792364
[No Abstract] [Full Text] [Related]
6. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
7. Management of protease inhibitor-associated hyperlipidemia.
Penzak SR; Chuck SK
Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
[TBL] [Abstract][Full Text] [Related]
8. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.
Graham NM
J Acquir Immune Defic Syndr; 2000 Oct; 25 Suppl 1():S4-11. PubMed ID: 11126425
[TBL] [Abstract][Full Text] [Related]
9. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.
Behrens G; Dejam A; Schmidt H; Balks HJ; Brabant G; Körner T; Stoll M; Schmidt RE
AIDS; 1999 Jul; 13(10):F63-70. PubMed ID: 10416516
[TBL] [Abstract][Full Text] [Related]
10. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
11. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
12. Lipid lowering therapy in patients with HIV infection.
McBride M; Chin MT; Lee SM; Kelly B
Lancet; 1998 Nov; 352(9142):1782-3. PubMed ID: 9848377
[No Abstract] [Full Text] [Related]
13. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
Stein JH; Klein MA; Bellehumeur JL; McBride PE; Wiebe DA; Otvos JD; Sosman JM
Circulation; 2001 Jul; 104(3):257-62. PubMed ID: 11457741
[TBL] [Abstract][Full Text] [Related]
14. Marked hyperlipidaemia on ritonavir therapy.
Sullivan AK; Nelson MR
AIDS; 1997 Jun; 11(7):938-9. PubMed ID: 9189227
[No Abstract] [Full Text] [Related]
15. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.
Smith D
J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199
[No Abstract] [Full Text] [Related]
17. Differentiating hyperlipidaemia associated with antiretroviral therapy.
Mauss S; Stechel J; Willers R; Schmutz G; Berger F; Richter WO
AIDS; 2003 Jan; 17(2):189-94. PubMed ID: 12545078
[TBL] [Abstract][Full Text] [Related]
18. Lipid abnormalities associated with protease inhibitors.
Melroe NH; Kopaczewski J; Henry K; Huebsch J
J Assoc Nurses AIDS Care; 1999; 10(2):22-30. PubMed ID: 10065407
[TBL] [Abstract][Full Text] [Related]
19. Hyperlipidemia associated with protease inhibitor therapy.
Echevarria KL; Hardin TC; Smith JA
Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
[TBL] [Abstract][Full Text] [Related]
20. LIPID abnormalities in patients infected with human immunodeficiency virus.
Mikhail NE
Endocr Pract; 2008; 14(4):492-500. PubMed ID: 18558606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
